DNA Mismatch Repair

• 

  Subject Areas on Research

  • A 'Semi-Protected Oligonucleotide Recombination' Assay for DNA Mismatch Repair in vivo Suggests Different Modes of Repair for Lagging Strand Mismatches. 
  • A possible mechanism for exonuclease 1-independent eukaryotic mismatch repair. 
  • ATR mutations in endometrial cancer: a window into the role of mismatch repair defects. 
  • Analysis of the excision step in human DNA mismatch repair. 
  • Association of family history with cancer recurrence and survival among patients with stage III colon cancer. 
  • Atomic force microscopy captures MutS tetramers initiating DNA mismatch repair. 
  • Atomic force microscopy captures the initiation of methyl-directed DNA mismatch repair. 
  • Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway. 
  • Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. 
  • Chromosome fragility at GAA tracts in yeast depends on repeat orientation and requires mismatch repair. 
  • Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger. 
  • Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens. 
  • CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. 
  • DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. 
  • DNA mismatch repair is required for the host innate response and controls cellular fate after influenza virus infection. 
  • DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. 
  • Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. 
  • Elevated risk of prostate cancer among men with Lynch syndrome. 
  • Endonuclease-independent DNA mismatch repair processes on the lagging strand. 
  • Frameshift mutagenesis: the roles of primer-template misalignment and the nonhomologous end-joining pathway in Saccharomyces cerevisiae. 
  • Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. 
  • Functions of MutLalpha, replication protein A (RPA), and HMGB1 in 5'-directed mismatch repair. 
  • Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis. 
  • Has Mismatch Repair-Deficient Cancer Met Its MATCH? 
  • Hereditary prostate cancer as a feature of Lynch syndrome. 
  • Heterogeneous polymerase fidelity and mismatch repair bias genome variation and composition. 
  • How should women with early-onset endometrial cancer be evaluated for lynch syndrome? 
  • Human MutLγ, the MLH1-MLH3 heterodimer, is an endonuclease that promotes DNA expansion. 
  • Hydrolytic function of Exo1 in mammalian mismatch repair. 
  • Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. 
  • Interaction of proliferating cell nuclear antigen with PMS2 is required for MutLα activation and function in mismatch repair. 
  • Interactions of human mismatch repair proteins MutSalpha and MutLalpha with proteins of the ATR-Chk1 pathway. 
  • MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. 
  • Mechanisms in E. coli and Human Mismatch Repair (Nobel Lecture). 
  • Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. 
  • Mismatch recognition and subsequent processing have distinct effects on mitotic recombination intermediates and outcomes in yeast. 
  • Mismatch repair and nucleotide excision repair proteins cooperate in the recognition of DNA interstrand crosslinks. 
  • Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. 
  • Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. 
  • Mismatch repair gone awry: Management of Lynch syndrome. 
  • Ninety-six haploid yeast strains with individual disruptions of open reading frames between YOR097C and YOR192C, constructed for the Saccharomyces genome deletion project, have an additional mutation in the mismatch repair gene MSH3. 
  • Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. 
  • Oligonucleotide transformation of yeast reveals mismatch repair complexes to be differentially active on DNA replication strands. 
  • PARP-1 enhances the mismatch-dependence of 5'-directed excision in human mismatch repair in vitro. 
  • PCNA function in the activation and strand direction of MutLα endonuclease in mismatch repair. 
  • PMS2 endonuclease activity has distinct biological functions and is essential for genome maintenance. 
  • Protein roadblocks and helix discontinuities are barriers to the initiation of mismatch repair. 
  • Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. 
  • Removal of N-6-methyladenine by the nucleotide excision repair pathway triggers the repair of mismatches in yeast gap-repair intermediates. 
  • Role of proliferating cell nuclear antigen interactions in the mismatch repair-dependent processing of mitotic and meiotic recombination intermediates in yeast. 
  • Saccharomyces cerevisiae MutLalpha is a mismatch repair endonuclease. 
  • Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. 
  • Sensing and Processing of DNA Interstrand Crosslinks by the Mismatch Repair Pathway. 
  • Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. 
  • Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management. 
  • Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. 
  • Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. 
  • Strand-biased spreading of mutations during somatic hypermutation. 
  • Structure of the endonuclease domain of MutL: unlicensed to cut. 
  • Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. 
  • The MutSalpha-proliferating cell nuclear antigen interaction in human DNA mismatch repair. 
  • The biochemistry of somatic hypermutation. 
  • The mechanism of nucleotide excision repair-mediated UV-induced mutagenesis in nonproliferating cells. 
  • The mismatch repair system promotes DNA polymerase zeta-dependent translesion synthesis in yeast. 
  • The mutagen and carcinogen cadmium is a high-affinity inhibitor of the zinc-dependent MutLα endonuclease. 
  • The polymerase eta translesion synthesis DNA polymerase acts independently of the mismatch repair system to limit mutagenesis caused by 7,8-dihydro-8-oxoguanine in yeast. 
  • Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. 
  • p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology